Neothetics (NEOT) Announces Initiation of Post-Treatment Safety, Effect Duration Study of LIPO-202
Tweet Send to a Friend
Neothetics (NASDAQ: NEOT) announced the initiation of the post-treatment safety and duration of effect study, LIPO-202-CL-23, of LIPO-202, the first ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
